Press Releases | Mylan http://newsroom.mylan.com/ MediaRoom Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries http://newsroom.mylan.com/2018-09-24-Mylan-Extends-Commitment-to-Fight-HIV-AIDS-by-Partnering-with-Atomo-Diagnostics-to-Expand-Access-to-HIV-Self-Testing-in-Low-and-Middle-Income-Countries Mon, 24 Sep 2018 07:00:00 -0400 http://newsroom.mylan.com/2018-09-24-Mylan-Extends-Commitment-to-Fight-HIV-AIDS-by-Partnering-with-Atomo-Diagnostics-to-Expand-Access-to-HIV-Self-Testing-in-Low-and-Middle-Income-Countries Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim http://newsroom.mylan.com/2018-09-21-Mylan-and-Biocon-Announce-Positive-CHMP-Opinion-for-Fulphila-R-Biosimilar-Pegfilgrastim Fri, 21 Sep 2018 09:30:00 -0400 http://newsroom.mylan.com/2018-09-21-Mylan-and-Biocon-Announce-Positive-CHMP-Opinion-for-Fulphila-R-Biosimilar-Pegfilgrastim Mylan Launches Authorized Generic of Ampyra® Tablets http://newsroom.mylan.com/2018-09-21-Mylan-Launches-Authorized-Generic-of-Ampyra-R-Tablets - Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis - Fri, 21 Sep 2018 08:57:00 -0400 http://newsroom.mylan.com/2018-09-21-Mylan-Launches-Authorized-Generic-of-Ampyra-R-Tablets Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab http://newsroom.mylan.com/2018-09-20-Mylan-and-Fujifilm-Kyowa-Kirin-Biologics-Receive-European-Marketing-Authorization-for-Hulio-R-Biosimilar-Adalimumab Thu, 20 Sep 2018 07:00:00 -0400 http://newsroom.mylan.com/2018-09-20-Mylan-and-Fujifilm-Kyowa-Kirin-Biologics-Receive-European-Marketing-Authorization-for-Hulio-R-Biosimilar-Adalimumab Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress http://newsroom.mylan.com/2018-09-17-Theravance-Biopharma-and-Mylan-Report-New-Data-from-Phase-3-Studies-of-YUPELRI-TM-revefenacin-in-Oral-Presentation-at-the-European-Respiratory-Society-International-Congress Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRI™ Compared to Placebo and Tiotropium (Spiriva ® HandiHaler ® ) Mon, 17 Sep 2018 08:30:00 -0400 http://newsroom.mylan.com/2018-09-17-Theravance-Biopharma-and-Mylan-Report-New-Data-from-Phase-3-Studies-of-YUPELRI-TM-revefenacin-in-Oral-Presentation-at-the-European-Respiratory-Society-International-Congress